CAS NO: | 1883429-22-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | BI-9564 is a potent, selective and cell-permeableBRD9/BRD7 bromodomainsinhibitor, withIC50s of 75 nM and 3.4 μM andKds of 14 nM and 239 nM, respectively. BI-9564 has anIC50of >100 μM for BET family[1]. | ||||||||||||||||
IC50& Target |
| ||||||||||||||||
体外研究 (In Vitro) | BI-9564 (<5 μm) shows no activity against 324 kinases, and at 10 μm, an inhibition>40% is observed for only 2 out of 55 GPCRs. BI-9564 has antiproliferative effect on human acute myeloid eosinophilic leukemia cell line EOL-1, with EC50of 800 nM[1]. BI-9564 shows Kdof 73 nM for BRD7, and is >10-fold more selective for BRD9 over the highly homologues bromodomain BRD7, which has been implied as a tumor suppressor and is down-regulated in cancer cells[2]. | ||||||||||||||||
体内研究 (In Vivo) | BI-9564 (180 mg/kg, p.o.) shows attractive ADME/PK profiles for in vivo proof-of-concept studies. BI-9564 results in a modest but significant additional survival benefit of 2 days compared to survival of the control group in a xenograft model of human AML[1]. | ||||||||||||||||
分子量 | 353.41 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C20H23N3O3 | ||||||||||||||||
CAS 号 | 1883429-22-8 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 8.33 mg/mL(23.57 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|